Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

No respite for Indian indices
Thu, 11 Jun Closing

After starting the day on a firm note, Indian markets weakened gradually as the day progressed. There was no respite in the final trading hour with the indices closing well below the dotted line. While the BSE-Sensex closed lower by 469 points, the NSE-Nifty closed lower by 160 points. The BSE Mid Cap and the BSE Small Cap indices were not spared either and closed lower by 1.8% each. Losses were largely seen in banking and auto stocks.

As regards to major global markets, European shares steadied in early trading after a strong rally in the previous session. Asian markets finished broadly higher today with shares in Japan leading the region. The Nikkei 225 is up 1.68% while Hong Kong's Hang Seng is up 0.84% and China's Shanghai Composite is up 0.30%.The rupee was trading at RS 63.89 against the American dollar in the afternoon session.

Profit booking was witnessed across majority of the FMCG sector with Colgate and Tata Global Beverages being the leading losers. According to a leading financial daily, Hindustan Unilever (HUL) has reportedly stopped sales and production of its Chinese range of instant noodles. The company has sought clearance from FSSAI and will resume sales of the products after getting approval. Reportedly, HUL conducted additional testing of its noodles range of products from external FSSAI approved laboratory last week to reassure consumers. The tests show that the Chinese noodles range of products are safe for consumption and continue to meet all regulatory norms. Further, HUL had submitted an application with FSSAI for product approval for the Knorr Chinese range of instant noodles in February 2015 and the same is pending approval. Shares of HUL ended the trading day in negative (down 0.24%) on the BSE.

Shares of Glenmark Pharmaceuticals surged after it was reported that the company has received final approval from the US health regulator for the generic Calcipotriene cream used for the treatment of plaque psoriasis. The product is the generic version of Leo Pharma A/S's Dovonex cream 0.005 per cent. Reportedly, the Dovonex market including brand and all available therapeutic equivalents, achieved an annual sales of approximately US$91.9 m. Glenmark's current portfolio consists of 98 products authorized for distribution in the US market and 67 ANDAs pending approval with USFDA.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "No respite for Indian indices". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.